During a discussion with colleagues about the best way to select small and new biotechnology firms for investment purposes, we started our answer by stating that selecting small and new biotechnology firms for investments is extremely challenging. As a matter of fact, the choice of firms for investment cannot be guaranteed approval of the firms’ products based on early and mid clinical trials' promising results, …

Krystal Biotech Today, February 26, 2024, Krystal Biotech (KRYS) firm announces its full year financial results and business updates.  Read this press release to learn about the company. New England Journal of Medicine publication of the use of B-VEC eyedrop formulation. Reached alignment with FDA to enable approval of B-VEC eyedrop formulation . . . This content is for paid subscribers. Please click here to subscribe …

Krystal Biotech Krystal Biotech (KRYS) is a gene therapy firm focused on developing topical intradermal therapeutics for rare dermatological diseases. It developed its a gene therapy product KB103 for the treatment of the broad Dystrophic epidermolysis bullosa (DEB) population, including both recessive and dominant forms of the disease. The vector that introduces the genes into dermal cells is an HSV . . . This content is for …